Alimera Sciences ALIM Stock
Alimera Sciences Price Chart
Alimera Sciences ALIM Financial and Trading Overview
| Alimera Sciences stock price | 3.52 USD |
| Previous Close | 2.81 USD |
| Open | 2.87 USD |
| Bid | 0 USD x 1800 |
| Ask | 0 USD x 3100 |
| Day's Range | 2.72 - 2.88 USD |
| 52 Week Range | 1.3 - 7.92 USD |
| Volume | 34.87K USD |
| Avg. Volume | 631.85K USD |
| Market Cap | 24.92M USD |
| Beta (5Y Monthly) | 1.381773 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.84 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7 USD |
ALIM Valuation Measures
| Enterprise Value | 63.06M USD |
| Trailing P/E | N/A |
| Forward P/E | 8.84375 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 0.44683376 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 1.131 |
| Enterprise Value/EBITDA | -7.788 |
Trading Information
Alimera Sciences Stock Price History
| Beta (5Y Monthly) | 1.381773 |
| 52-Week Change | -47.49% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 7.92 USD |
| 52 Week Low | 1.3 USD |
| 50-Day Moving Average | 2.21 USD |
| 200-Day Moving Average | 3.32 USD |
ALIM Share Statistics
| Avg. Volume (3 month) | 631.85K USD |
| Avg. Daily Volume (10-Days) | 108.24K USD |
| Shares Outstanding | 8.81M |
| Float | 4.05M |
| Short Ratio | 0.46 |
| % Held by Insiders | 19.40% |
| % Held by Institutions | 28.59% |
| Shares Short | 791.61K |
| Short % of Float | 11.30% |
| Short % of Shares Outstanding | 8.98% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:15 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -30.69% |
| Operating Margin (ttm) | -19.35% |
| Gross Margin | 85.07% |
| EBITDA Margin | -14.51% |
Management Effectiveness
| Return on Assets (ttm) | -13.74% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 55.78M USD |
| Revenue Per Share (ttm) | 7.96 USD |
| Quarterly Revenue Growth (yoy) | 13.90% |
| Gross Profit (ttm) | N/A |
| EBITDA | -8097000 USD |
| Net Income Avi to Common (ttm) | -17134000 USD |
| Diluted EPS (ttm) | -2.76 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 13.09M USD |
| Total Cash Per Share (mrq) | 1.77 USD |
| Total Debt (mrq) | 47.53M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 2.517 |
| Book Value Per Share (mrq) | -3.605 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -5971000 USD |
| Levered Free Cash Flow (ttm) | 59.13K USD |
Profile of Alimera Sciences
| Country | United States |
| State | GA |
| City | Alpharetta |
| Address | 6310 Town Square |
| ZIP | 30005 |
| Phone | 678 990 5740 |
| Website | https://alimerasciences.com |
| Industry | Drug Manufacturers-Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 150 |
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals. It operates through United States, internationally, and Operating Cost segments. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, clinics, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
Q&A For Alimera Sciences Stock
What is a current ALIM stock price?
Alimera Sciences ALIM stock price today per share is 3.52 USD.
How to purchase Alimera Sciences stock?
You can buy ALIM shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Alimera Sciences?
The stock symbol or ticker of Alimera Sciences is ALIM.
Which industry does the Alimera Sciences company belong to?
The Alimera Sciences industry is Drug Manufacturers-Specialty & Generic.
How many shares does Alimera Sciences have in circulation?
The max supply of Alimera Sciences shares is 52.35M.
What is Alimera Sciences Price to Earnings Ratio (PE Ratio)?
Alimera Sciences PE Ratio is now.
What was Alimera Sciences earnings per share over the trailing 12 months (TTM)?
Alimera Sciences EPS is -0.84 USD over the trailing 12 months.
Which sector does the Alimera Sciences company belong to?
The Alimera Sciences sector is Healthcare.
Alimera Sciences ALIM included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Market Composite NQGM | 2160.36 USD — |
-2.45
|
— — | 2147.48 USD — | 2200.33 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| NASDAQ Composite Total Return I XCMP | 19659.36 USD — |
-1.62
|
— — | 19598.88 USD — | 19861.56 USD — | — - | — — |
- {{ link.label }} {{link}}